Precigen, Inc. (NASDAQ:PGEN) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC cut its holdings in Precigen, Inc. (NASDAQ:PGEN - Free Report) by 33.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,067,645 shares of the biotechnology company's stock after selling 532,545 shares during the quarter. Renaissance Technologies LLC owned about 0.36% of Precigen worth $1,196,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of PGEN. Stifel Financial Corp grew its holdings in shares of Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company's stock worth $30,000 after buying an additional 15,680 shares during the last quarter. State Street Corp lifted its position in Precigen by 1.0% during the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company's stock worth $2,720,000 after acquiring an additional 29,253 shares during the period. Barclays PLC grew its stake in shares of Precigen by 190.4% in the 3rd quarter. Barclays PLC now owns 189,353 shares of the biotechnology company's stock valued at $179,000 after purchasing an additional 124,141 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Precigen by 4.8% in the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company's stock valued at $3,075,000 after purchasing an additional 149,829 shares during the period. Finally, Synovus Financial Corp raised its stake in shares of Precigen by 100.0% during the third quarter. Synovus Financial Corp now owns 98,130 shares of the biotechnology company's stock worth $93,000 after purchasing an additional 49,065 shares during the last quarter. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PGEN has been the topic of a number of analyst reports. JMP Securities reiterated a "market outperform" rating and issued a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th. HC Wainwright reaffirmed a "buy" rating and issued a $6.00 target price on shares of Precigen in a report on Thursday, March 20th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Precigen currently has an average rating of "Moderate Buy" and an average price target of $7.00.

Precigen Stock Down 0.6 %

Shares of NASDAQ PGEN opened at $1.54 on Wednesday. The firm has a 50-day moving average price of $1.59 and a 200 day moving average price of $1.25. Precigen, Inc. has a 52 week low of $0.65 and a 52 week high of $2.17. The stock has a market capitalization of $452.83 million, a price-to-earnings ratio of -2.80 and a beta of 1.70.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.02. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%. The business had revenue of $1.19 million for the quarter, compared to analyst estimates of $1.30 million. Equities research analysts expect that Precigen, Inc. will post -0.32 EPS for the current fiscal year.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.

Want to see what other hedge funds are holding PGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Precigen, Inc. (NASDAQ:PGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.